We are convinced that better information is needed to enhance human and environmental health in a sustainable way. We have embarked on a journey to revolutionize diagnostics.
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules.
We will help transform point of care testing and third generation sequencing.
We are ONTERA, a grounded company with ambitious dreams of improving the Earth.
As CEO, Murielle brings her expertise in healthcare and business strategy to revolutionize point of care molecular diagnostics.
Most recently she was the COO of Genome Medical, a genetics telehealth practice where she was responsible for product, engineering, business development, sales and marketing. Prior to that, she was an Executive in Residence for GE Healthcare Ventures. Previously, she spent 7 years as an executive at McKesson and held a variety of positions at Novartis, Genentech, and UnitedHealth/OptumHealth.
Murielle has an MBA in Healthcare Management from the Wharton School and a Master’s degree in Finance from Université Jean Moulin, Lyon, France.
In her spare time, she serves on the executive council on pharmaceuticals and digital health of Springboard Enterprises, a highly-vetted expert network of innovators, investors and influencers dedicated to building high-growth technology-oriented companies led by women.
Bill co-founded Ontera (then called Two Pore Guys), and currently serves as Chief Technology Officer to lead data analysis and IP creation and oversight for all of Ontera’s technologies.
Prior to Ontera, Bill was an engineering professor for 12 years at University of California Santa Cruz, publishing over 50 peer-reviewed papers and earning the National Science Foundation's prestigious CAREER award. Bill is co-inventor on 10 issued patents on diverse topics, from self-driving cars (owned by Toyota) to nanopore sequencing (licensed by Oxford Nanopore Technologies). Bill invented the dual nanopore device at UC Santa Cruz in 2011, and co-founded Ontera to license and commercialize that IP for applications that include structural variation detection, genome mapping and chemistry-free polynucleotide sequencing.
Bill received a Ph.D. in control and dynamical systems theory from California Institute of Technology (Caltech) .
Trevor was employee number one of Ontera (then called Two Pore Guys), and currently serves as CSO, focusing on the company’s technology, strategic planning and innovation.
Trevor built and has lead the R&D department at Ontera from its inception. Prior to that, Trevor enjoyed careers in both drug discovery & development, and vaccine design for infectious diseases. He has shepherded novel drug biologics and vaccines through discovery and development, into manufacturing and FDA trials. Trevor has authored several peer-reviewed publications and patents.
Trevor received a Ph.D. in Biochemistry and Molecular Pharmacology from the School of Biological Sciences at the University of Massachusetts Medical School after completing an Animal Science degree at Mount Ida College and Biology/Chemistry degree at UMass Boston.
As SVP of Engineering, Andrea is leading a multi-disciplinary team to develop our platforms for fast and accurate sample-to-answer molecular diagnostics using high sensitivity nanopore sensors.
Andrea brings over two decades of product development experience integrating microfluidics, laboratory automation, and assay technologies for research and medical device uses.
She has held senior leadership positions in BioElectron, Promega, and Caliper, where she built teams and provided innovative vision from conceptualization to commercialization of 9 products.
Andrea holds a PhD in chemical engineering from Stanford University. She has served on advisory boards including the National Academies, Lab-on-a-Chip Journal, and the Association for Laboratory Automation. She was named among “100 Chemical Engineers of the Modern Era” by the American Institute of Chemical Engineers in 2008.